Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer By Ogkologos - July 15, 2025 766 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Inside Cancer Grand Challenges Part 1: what makes a grand challenge? June 16, 2022 Manipulating an Immune Cell May Make Radiation Therapy More Effective, Study... February 12, 2024 FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... July 25, 2025 Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... January 17, 2023 Load more HOT NEWS Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced... Grandparents of children with cancer: “I would never want to go... Popular Fitness Instructor Encourages Others to Maintain Routine Check Ups After... EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab
